After TMZ treatment, the tumor volumes of the HIF1α-and/or HIF2α-knockout groups were significantly (p < 0.01) reduced, and those of the dual-knockout group were lower than those of the single-knockout groups (Figures 3F,H). The gene discussed is EPAS1; the disease is neoplasm.